Name: Pharmaceutical Preparations Stocks in USA: Revenue Cohort 2 comparison snapshot
Creator: Fliar BI Prism

01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1ALNY · Nasdaq

Alnylam

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2002Cambridge, Massachusetts$31.73B market cap

View full Companies Radar profile

59Moderate

Snapshot price$237.1as of page date

Monthly-close return+17.4%five-year window

FY2025 revenue$3.71BALNYLAM PHARMACEUTICALS, INC.

Net margin8.4%FY2025

P/E snapshot41.3xone ratio, not a verdict

Prism attention21.7%share across these five

Filing track recordRevenue, USD billions

+127966.8%

FY2019–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 498.2%

52-week position13% through range

$197.8$495.6

News mentions4.7K

Community mentions79partial coverage

U.S.-scope patents4606

Prism InsightsWhat sits behind the readiness signal
Observed risk 7/100higher means more observed risk

Earnings signal76/100
Management stability90/100
Market position15/100
Capital-event signal86/100
Innovation pulse25/100

Management signal

No leadership-churn flag in the model; 10 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 8 M&A involvements, 2 asset-acquisition events and 11 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 7 company announcements in that window.

Recent risk watch

Recent available records contain 0 lawsuit, 2 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2ONC · Nasdaq

BeiGene

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2010Cambridge$41.49B market cap

View full Companies Radar profile

57Moderate

Snapshot price$366.7as of page date

Monthly-close return+20.8%five-year window

FY2025 revenue$5.34BBeOne Medicines Ltd.

Net margin5.4%FY2025

P/E snapshot65.8xone ratio, not a verdict

Prism attention23.0%share across these five

Filing track recordRevenue, USD billions

+1629.8%

FY2020–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 103.9%

52-week position86% through range

$253.9$385.2

News mentions5.0K

Community mentions58partial coverage

U.S.-scope patents56

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal79/100
Management stability90/100
Market position13/100
Capital-event signal74/100
Innovation pulse10/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 5 M&A involvements, 2 asset-acquisition events and 5 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3BHC · NYSE

Solta

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 1999Hayward, California$2.36B market cap

View full Companies Radar profile

54Moderate

Snapshot price$6.32as of page date

Monthly-close return-78.4%five-year window

FY2025 revenue$10.27BBausch Health Companies Inc.

Net margin1.5%FY2025

P/E snapshot1.5xone ratio, not a verdict

Prism attention15.3%share across these five

Filing track recordRevenue, USD billions

+21.7%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 5.0%

52-week position54% through range

$4.33$8.00

News mentions3.3K

Community mentions18partial coverage

U.S.-scope patents170

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal65/100
Management stability90/100
Market position14/100
Capital-event signal67/100
Innovation pulse22/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 14 M&A involvements, 0 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 1 lifetime product-launch events, 1 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4ELAN · NYSE

Elanco

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 1954INDIANAPOLIS$12.05B market cap

View full Companies Radar profile

45Cautious

Snapshot price$24.11as of page date

Monthly-close return-26.6%five-year window

FY2025 revenue$4.71BElanco Animal Health Inc

Net margin-4.9%FY2025

P/E snapshot18.8xone ratio, not a verdict

Prism attention17.2%share across these five

Filing track recordRevenue, USD billions

-1.0%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -0.3%

52-week position64% through range

$17.11$27.98

News mentions3.8K

Community mentions85partial coverage

U.S.-scope patents813

Prism InsightsWhat sits behind the readiness signal
Observed risk 8/100higher means more observed risk

Earnings signal50/100
Management stability90/100
Market position28/100
Capital-event signal69/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 23 M&A involvements, 18 asset-acquisition events and 3 contract events.

Innovation activity

Prism records 2 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 1 lawsuit, 1 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5PRGO · NYSE

Perrigo

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 1887LANSING$2.01B market cap

View full Companies Radar profile

44Cautious

Snapshot price$14.48as of page date

Monthly-close return-64.9%five-year window

FY2025 revenue$4.25BPERRIGO Co plc

Net margin-33.5%FY2025

P/E snapshot6.0xone ratio, not a verdict

Prism attention22.8%share across these five

Filing track recordRevenue, USD billions

+2.8%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 0.7%

52-week position36% through range

$9.23$23.95

News mentions5.0K

Community mentions632partial coverage

U.S.-scope patents95

Prism InsightsWhat sits behind the readiness signal
Observed risk 18/100higher means more observed risk

Earnings signal41/100
Management stability90/100
Market position35/100
Capital-event signal76/100
Innovation pulse18/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 137 M&A involvements, 42 asset-acquisition events and 14 contract events.

Innovation activity

Prism records 6 lifetime product-launch events, 0 in the latest 360 days, and 1 company announcements in that window.

Recent risk watch

Recent available records contain 9 lawsuit, 1 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

BeiGene

+20.8%

Alnylam

+17.4%

Elanco

-26.6%

Perrigo

-64.9%

Solta

-78.4%

Latest revenue

USD billions, official filing scope shown on each company card.

Solta

$10.27B

BeiGene

$5.34B

Elanco

$4.71B

Perrigo

$4.25B

Alnylam

$3.71B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

Alnylam

8.4%

BeiGene

5.4%

Solta

1.5%

Elanco

-4.9%

Perrigo

-33.5%

Prism news attention

Normalized share across these five names; attention is not quality.

BeiGene

23.0%

Perrigo

22.8%

Alnylam

21.7%

Elanco

17.2%

Solta

15.3%

03 · Prism readout

What the signals say—and what they do not

The headline share is normalized pharmaceutical preparations news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

BeiGene leads the conversation

It holds 23.0% of measured pharmaceutical preparations news attention and also carries the basket's largest revenue base at $5.34B.

Price path

BeiGene leads the available price paths

Its monthly-close return is +20.8% for the five-year window. At the other end, Solta is -78.4% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

Alnylam has the widest latest margin

Its FY2025 net margin is 8.4%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

Solta shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at 1.5x while its five-year window price return is -78.4%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · ALNY

Alnylam

4,713available Prism news records

Prism top themes

Price action & investor response

412

Capital allocation & transactions

278

Earnings & financial performance

88

Legal, arbitration & regulatory

38

Leadership & governance

31

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+1.0%684 latest 12m vs 677 prior 12m

Machine-classified coverage tone

90.8% positive+4.6 pp vs preceding four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

gene therapy rare diseases 123stock performance 112investment deal 94company valuation 43orphan drug pricing 36rare disease treatment 35angel investors 33gene delivery systems 32

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-07–2026-08-02 · trend and themes shown through 2026-08

Areas of research · ONC

BeiGene

5,010available Prism news records

Prism top themes

Legal, arbitration & regulatory

113

Earnings & financial performance

89

Price action & investor response

68

Capital allocation & transactions

41

Leadership & governance

37

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-34.7%588 latest 12m vs 900 prior 12m

Machine-classified coverage tone

94.5% positive+3.1 pp vs preceding four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

angiogenesis inhibitors 75cancer biomarkers 52checkpoint inhibitors lymphoma 44adc therapeutics 30antibody-drug conjugates lymphoma 30stock performance 25t-cell lymphoma 23burkitt lymphoma 22

Keyword tag occurrences in available Prism news records.

Coverage: 2010-10-28–2026-07-16 · trend and themes shown through 2026-07

Areas of research · BHC

Solta

3,339available Prism news records

Prism top themes

Price action & investor response

103

Earnings & financial performance

89

Capital allocation & transactions

75

Leadership & governance

39

Legal, arbitration & regulatory

27

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-22.3%421 latest 12m vs 542 prior 12m

Machine-classified coverage tone

94.3% positive+1.5 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

generic drug approval 37stock performance 27earnings report 24quarterly financials 16financial report 15company valuation 15annual earnings 15quarterly results 14

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-08–2026-06-11 · trend and themes shown through 2026-06

Areas of research · ELAN

Elanco

3,750available Prism news records

Prism top themes

Earnings & financial performance

113

Price action & investor response

74

Legal, arbitration & regulatory

71

Leadership & governance

68

Capital allocation & transactions

19

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-23.3%532 latest 12m vs 694 prior 12m

Machine-classified coverage tone

83.9% positive+18.4 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

dairy cows 23class action securities litigation 23vaccine formulation 23quarterly results 22earnings report 20annual earnings 19stock performance 19milk production 18

Keyword tag occurrences in available Prism news records.

Coverage: 2010-02-01–2026-06-19 · trend and themes shown through 2026-06

Areas of research · PRGO

Perrigo

4,952available Prism news records

Prism top themes

Price action & investor response

103

Earnings & financial performance

54

Capital allocation & transactions

38

Leadership & governance

29

Legal, arbitration & regulatory

16

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+11.3%316 latest 12m vs 284 prior 12m

Machine-classified coverage tone

66.9% positive-3.0 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stock performance 11wearable tech 10wearable device 10private equity 10earnings report 9ceo change 8earnings surprises 8generic drug approval 8

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-07–2026-06-15 · trend and themes shown through 2026-06

05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

ALNY

Alnylam

79 mentions

Stock and valuation

36

Products, pricing and logistics

14

Workplace and hiring

3

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 79 records remained after filtering.

ONC

BeiGene

58 mentions

Stock and valuation

19

Products, pricing and logistics

11

Workplace and hiring

2

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 58 records remained after filtering.

ELAN

Elanco

85 mentions

Stock and valuation

44

Products, pricing and logistics

8

Workplace and hiring

5

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 85 records remained after filtering.

PRGO

Perrigo

632 mentions

Products, pricing and logistics

427

Stock and valuation

83

Workplace and hiring

13

Other company context

2

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 632 records remained after filtering.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

ALNY

Alnylam

through 2026-03-10

Earnings releases 43Leadership changes 10Company announcements 9Listing / IPO 6Lawsuits 5

2026-03-10
Company announcements
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming TTR Investor Webinar on the Investors section of the Company’s website, www.alnylam.com, on Tuesday, March 24, 2026 at 9:30 am ET.
2026-02-17
Earnings releases
For the full year 2025, the company reported a net income of roughly $314 million on revenue of about $3.71 billion.
2026-02-12
Leadership changes
Previously, from 2004 to 2011, Ms. Allen served as the Vice President of Finance, Treasurer, and Principal Financial Officer of Alnylam Pharmaceuticals, Inc.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

ONC

BeiGene

through 2025-12-31

Company announcements 14Earnings releases 12Leadership changes 7Business contracts 3Lawsuits 3

2025-12-31
Asset acquisitions
The company has entered into a purchase agreement to acquire an approximately 42-acre site with over one million square feet of developable real estate.
2025-02-27
Earnings releases
Total revenue $ 1,127,824 $ 634,409 78 % $ 3,810,241 $ 2,458,779 55 %
2025-02-14
Listing / IPO
Beigene Ltd. priced its Hong Kong IPO and global offering of 65.6 million ordinary shares with gross proceeds expected to be approximately HK$7.08 billion (US$903 million).

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

BHC

Solta

through 2025-12-01

M&A 4

2025-12-01
M&A
today announced the successful completion of the acquisition of Wuhan Shibo Zhenmei Technology Co., Ltd., consisting of the Shibo group's aesthetics distribution business.
2025-12-01
M&A
Along with its global aesthetic business, Solta Medical, today announced the successful completion of the acquisition of Wuhan Shibo Zhenmei Technology Co., Ltd., consisting of the Shibo group's aesthetics distribution business. Effective December 1, 2025, Wuhan Shibo Zhenmei Technology Co., Ltd. became a wholly owned subsidiary of Solta Medical in China, assuming full responsibility for the distribution of Solta Medical's products, including Thermage® FLX, as well as other aesthetic devices in the Chinese market.
2025-02-14
M&A
Solta Medical (Hayward, California), a medical aesthetics company, said it has completed its acquisition of Aesthera (Pleasanton, California) for $5.25 million in Solta common stock and cash, with potential additional base line milestones of $750,000 for a total consideration of $6 million.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

ELAN

Elanco

through 2025-11-04

Earnings releases 10Lawsuits 2M&A 2Asset acquisitions 1Regulatory 1

2025-11-04
Earnings releases
Elanco beat analysts’ revenue expectations by 4.7% last quarter, reporting revenues of $1.24 billion, up 4.8% year on year.
2025-10-23
Lawsuits
Elanco 401k investors have sued the company.
2025-10-05
Regulatory
Based on supplemental scientific data, the FDA provided an update to Elanco’s Zenrelia label, removing the risk of fatal vaccine-induced disease from modified live virus vaccine from the labeling.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

PRGO

Perrigo

through 2026-04-30

Earnings releases 22Leadership changes 13Lawsuits 5M&A 5Company announcements 4

2026-04-30
Asset acquisitions
Perrigo Company plc ... today announced that it has completed the previously announced sale of its branded Dermacosmetics business to Karo Healthcare for total consideration of up to €332.6 million.
2026-02-26
Earnings releases
Net sales of $1.11 billion decreased 2.5%, or $29 million, including favorable currency translation of 2.3% and divestitures and exited products of -0.4%.
2026-02-17
Lawsuits
An investor who purchased shares of Perrigo Company plc (NYSE: PRGO), filed a lawsuit over alleged violations of Federal Securities Laws by Perrigo Company plc.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Pharmaceutical Preparations Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary pharmaceutical preparations news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

pharmaceutical industry

36 sources100.0% extraction confidence

2011 extracted base$66.70B

2016 extracted forecast$42.00B–$70.00B

Implied source CAGR9.5%

Macro and micro trends driving the industry's futureR&D expenditure and leading therapeutic areasGrowth opportunities

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, India, China, U.S.. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Pharmaceutical Preparations news pulse

55,282available Prism news records

Latest 12m volume+3.4%24052 vs 23272 records

Positive classified tone65.3%+6.0 pp vs prior four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Available U.S.-primary Prism records matching pharmaceutical, preparation. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

drug pricing and reimbursement strategies

6,223

snowstorm and blizzard alerts

6,121

pharmaceutical marketing and sales strategies

6,014

winter weather preparedness

5,925

generic drug development and market trends

3,700

healthcare economics and market access

3,498

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

ice storm preparation 6,522snowstorm advisory 5,649cold weather readiness 5,010heavy snow warning 4,972winter storm alert 4,355snow accumulation alert 4,114life-threatening weather 2,915severe weather warning 2,905

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

Macro and micro trends driving the industry's future

36 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card

Opportunity · demand

drug pricing and reimbursement strategies

6,223 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata

Opportunity · innovation

Innovation and product activity

5,689 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule

Caution · market restraint

regulatory changes

5,709 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata

Caution · news pulse

Coverage growth can reverse

+3.4% news volume

The latest 12 months contain 24,052 matched records versus 23,272 in the previous window.

Available Prism coverage through 2026-05-05

Caution · sentiment

Classified tone is not demand

65.3% positive · +6.0pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →

08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 2834 (Pharmaceutical Preparations), selected as the first five names that pass all live publication gates from the latest filing revenue candidate pool ranked 6–13. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

Official annual filingsFY revenue history and latest profitability
U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
Prism market-growth extractionDated third-party Pharmaceutical Preparations Industry in USA market benchmark with source-count, geography and confidence context

Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 28 August 2026.

09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions

Alnylam leads the readiness ranking

Its Prism readiness score is 59/100, the highest in this five-company comparison.

Open Alnylam in Companies Radar

Scale and margin leadership sit with Solta and Alnylam

Solta has the largest displayed latest revenue at $10.27B; Alnylam has the widest displayed latest margin at 8.4%.

Open Solta in Companies Radar Open Alnylam in Companies Radar

Comparisons

Strongest versus weakest available price path

BeiGene is +20.8% for its five-year window; Solta is -78.4% for its five-year window.

Open BeiGene in Companies Radar Open Solta in Companies Radar

Largest versus smallest displayed revenue base

The latest displayed revenue ranges from $10.27B for Solta to $3.71B for Alnylam. Entity and filing-period labels remain visible on the company cards.

Open Solta in Companies Radar Open Alnylam in Companies Radar

Anomalies

Perrigo has the widest attention-readiness rank gap

It ranks #2 by measured news attention (22.8%) and #5 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open Perrigo in Companies Radar

Solta shows a price-operating divergence to inspect

Its displayed filing-revenue change is +21.7% while its available monthly-close return is -78.4%. The signs differ, but the two measures cover different windows and do not establish causality.

Open Solta in Companies Radar

Explanations

Attention measures coverage volume, not quality

BeiGene's 23.0% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open BeiGene in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open Alnylam's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 59/100 score.

Open Alnylam in Companies Radar

Stress-test the largest divergence before forming a view

Compare Solta's profile with BeiGene's profile, then reconcile the displayed filing and price windows. This is a next-research action, not a buy or sell decision.

Open Solta in Companies Radar Open BeiGene in Companies Radar

Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.